Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATR-101 in congenital adrenal hyperplasia
NCT02804178Phase 2Completed
- Sponsor
- Millendo Therapeutics
- Start
- May 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Nevanimibe in congenital adrenal hyperplasia (CAH), sponsored by Millendo Therapeutics. Started May 2016; status: completed.
02
Drugs
Nevanimibe
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT02804178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02804178.